Alternatively, binding of CTCF/SMARCA5 at −14.4 Enhancer is aberrant and specific for AML undergoing DNA demethylation and may not exist in normal progenitor physiology. This evidence concerns the gene SMARCA5 and acute myeloid leukemia.